aminocaproic acid has been researched along with Innate Inflammatory Response in 15 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of ϵ-acetamidocaproic acid (AACA) were evaluated after the intravenous and oral administration of an antiulcer agent, zinc acexamate (ZAC) at a dose of 20 mg kg⁻¹ (ion pairing between zinc and AACA) in rats with indomethacin-induced acute gastric ulcer (IAGU) or indomethacin-induced small bowel inflammation (ISBI)." | 3.78 | ε-Acetamidocaproic acid pharmacokinetics in rats with gastric ulcer or small bowel inflammation. ( Choi, YH; Kim, YG; Lee, BK; Lee, MG; Lee, U; Oh, E, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (60.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Wallen, TE | 1 |
| Singer, KE | 1 |
| Baucom, MR | 1 |
| England, LG | 1 |
| Schuster, RM | 1 |
| Pritts, TA | 1 |
| Goodman, MD | 1 |
| Two, AM | 1 |
| Hata, TR | 1 |
| Nakatsuji, T | 1 |
| Coda, AB | 1 |
| Kotol, PF | 1 |
| Wu, W | 1 |
| Shafiq, F | 1 |
| Huang, EY | 1 |
| Gallo, RL | 1 |
| Lee, U | 1 |
| Choi, YH | 1 |
| Kim, YG | 1 |
| Lee, BK | 1 |
| Oh, E | 1 |
| Lee, MG | 1 |
| Balaguer, JM | 1 |
| Yu, C | 1 |
| Byrne, JG | 1 |
| Ball, SK | 1 |
| Petracek, MR | 1 |
| Brown, NJ | 1 |
| Pretorius, M | 1 |
| FERLUGA, J | 1 |
| NIKULIN, A | 1 |
| STERN, P | 1 |
| ALLISON, F | 2 |
| LANCASTER, MG | 2 |
| CROSTHWAITE, JL | 1 |
| FLANDRE, MO | 1 |
| DAMON, M | 1 |
| PEILLEX, F | 1 |
| FRANCOIS, P | 1 |
| BURKE, JS | 1 |
| URIUHARA, T | 1 |
| MACMORINE, DR | 1 |
| MOVAT, HZ | 1 |
| Brosnan, CF | 1 |
| Cammer, W | 1 |
| Norton, WT | 1 |
| Bloom, BR | 1 |
| Velky, TS | 1 |
| Greenburg, AG | 1 |
| Yang, JC | 1 |
| Forbes, S | 1 |
| Nakagawa, H | 1 |
| Shuto, K | 1 |
| Isaji, M | 1 |
| Watanabe, K | 1 |
| Tsurufuji, S | 1 |
| Higazi, AA | 1 |
| Barghouti, II | 1 |
| Ayesh, SK | 1 |
| Mayer, M | 1 |
| Matzner, Y | 1 |
| van Waarde, D | 1 |
| Hulsing-Hesselink, E | 1 |
| van Furth, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bradykinin Receptor Antagonism During Cardiopulmonary Bypass[NCT00223704] | Phase 2/Phase 3 | 150 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Units of Packed Red Blood Cells Transfused (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | units (Mean) |
|---|---|
| Placebo Group | 1.97 |
| Aminocaproic Acid Group | 1.41 |
| HOE 140 Group | 1.45 |
Units of plasma transfused (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | units (Mean) |
|---|---|
| Placebo Group | 1.08 |
| Aminocaproic Acid Group | 0.68 |
| HOE 140 Group | 0.82 |
Blood product transfusion during hospitalization that included packed red blood cells, plasma, platelets and cryoprecipitate. (NCT00223704)
Timeframe: Patients were followed for the duration of hospital stay, an average of 6 days
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Received any transfusion | Received packed red blood cells | Received plasma | Received platelets | Received cryoprecipitate | |
| Aminocaproic Acid Group | 56.8 | 48.6 | 24.3 | 16.2 | 2.7 |
| HOE 140 Group | 52.5 | 47.5 | 17.5 | 17.5 | 5.0 |
| Placebo Group | 47.4 | 36.8 | 31.6 | 23.7 | 10.5 |
D-dimer concentrations were measured at baseline, 30min and 60min of bypass, post-bypass and postoperative day 1 (NCT00223704)
Timeframe: Patients were followed from the start of surgery until postoperative day 1
| Intervention | ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 30min of bypass | 60min of bypass | Post-bypass | Postoperative day 1 | |
| Aminocaproic Acid Group | 103.0 | 131.9 | 154.3 | 168.9 | 269.5 |
| HOE 140 Group | 88.1 | 209.0 | 363.3 | 858.5 | 337.3 |
| Placebo Group | 95.5 | 150.6 | 287.6 | 589.8 | 390.4 |
Interleukin-6 was measured at baseline, post-bypass and on postoperative day 1 and 2. (NCT00223704)
Timeframe: Patients were followed from the start of surgery until postoperative day 2
| Intervention | pg/ml (Mean) | |||
|---|---|---|---|---|
| Baseline | Post-bypass | Postoperative day 1 | Postoperative day 2 | |
| Aminocaproic Acid Group | 6.58 | 64.65 | 161.91 | 122.88 |
| HOE 140 Group | 4.80 | 142.02 | 166.27 | 86.54 |
| Placebo Group | 4.98 | 68.8 | 118.8 | 201.5 |
2 trials available for aminocaproic acid and Innate Inflammatory Response
| Article | Year |
|---|---|
Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminocaproic Acid; Antimicrobial Cationic P | 2014 |
Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Transfusion; Bradykinin; Bradykinin Receptor Antag | 2013 |
13 other studies available for aminocaproic acid and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Effects of antifibrinolytics on systemic and cerebral inflammation after traumatic brain injury.
Topics: Aminocaproic Acid; Animals; Antifibrinolytic Agents; Brain Injuries, Traumatic; Chemokine CCL2; Chem | 2022 |
ε-Acetamidocaproic acid pharmacokinetics in rats with gastric ulcer or small bowel inflammation.
Topics: Administration, Oral; Aminocaproates; Aminocaproic Acid; Animals; Anti-Ulcer Agents; Arteries; Blood | 2012 |
[The antiphlogistic effect of epsilon-amino-caproic acid].
Topics: Aminocaproic Acid; Caproates; Inflammation | 1963 |
STUDIES ON THE PATHOGENESIS OF ACUTE INFLAMMATION. V. AN ASSESSMENT OF FACTORS THAT INFLUENCE IN VITRO THE PHAGOCYTIC AND ADHESIVE PROPERTIES OF LEUKOCYTES OBTAINED FROM RABBIT PERITONEAL EXUDATE.
Topics: Adhesives; Aminocaproates; Aminocaproic Acid; Animals; Antimetabolites; Calcium; Edetic Acid; Enzyme | 1963 |
[ACTION OF EPSILON-AMINOCAPROIC ACID ON THE FORMATION OF INFLAMMATORY CONNECTIVE TISSUE].
Topics: Aminocaproates; Aminocaproic Acid; Connective Tissue; Foreign Bodies; Granuloma; Inflammation; Patho | 1964 |
A PERMEABILITY FACTOR RELEASED FROM PHAGOCYTOSING PMN-LEUKOCYTES AND ITS INHIBITION BY PROTEASE INHIBITORS.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Antigen-Antibody Reactions; Aprotinin; Capillary Permeab | 1964 |
PATHOGENESIS OF ACUTE INFLAMMATION. VI. INFLUENCE OF OSMOLARITY AND CERTAIN METABOLIC ANTAGONISTS UPON PHAGOCYTOSIS AND ADHESIVENESS BY LEUCOCYTES RECOVERED FROM MAN.
Topics: Adhesiveness; Aminocaproates; Aminocaproic Acid; Citrulline; Dinitrophenols; Edetic Acid; Glycine; H | 1965 |
Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis.
Topics: Aminocaproic Acid; Animals; Aprotinin; Benzoates; Encephalomyelitis, Autoimmune, Experimental; Guani | 1980 |
Modulators of plasma fibronectin response during sepsis.
Topics: Aminocaproic Acid; Animals; Blood Coagulation; Cecum; Endotoxins; Escherichia coli; Fibronectins; In | 1984 |
Proteinase inhibitors suppress the formation of granulation tissue in the carrageenin-induced inflammation in rats.
Topics: Aminocaproic Acid; Animals; Benzenesulfonates; Carrageenan; Granulation Tissue; Inflammation; Male; | 1981 |
Inhibition of neutrophil activation by fibrinogen.
Topics: Amino Acids; Aminocaproic Acid; Antibodies, Monoclonal; CD18 Antigens; Chemotaxis, Leukocyte; Comple | 1994 |
Properties of a factor increasing monocytopoiesis (FIM) occurring in serum during the early phase of an inflammatory reaction.
Topics: Aminocaproic Acid; Animals; Ascitic Fluid; Blood Coagulation Tests; Blood Preservation; Bone Marrow | 1977 |